Wedbush Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with an Outperform rating and a price target of $12.
April 02, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush initiated coverage on Prime Medicine with an Outperform rating and a price target of $12.
The initiation of coverage by Wedbush with an Outperform rating and a price target of $12 suggests a positive outlook for Prime Medicine's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100